These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 15316429)

  • 21. Pentasaccharides. The new anticoagulants.
    Abdel-Razeq H
    Saudi Med J; 2004 Aug; 25(8):983-90. PubMed ID: 15322584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prophylaxis of venous thromboembolism in medical patients.
    Gerotziafas GT; Samama MM
    Curr Opin Pulm Med; 2004 Sep; 10(5):356-65. PubMed ID: 15316432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology.
    Bauer KA
    Chest; 2003 Dec; 124(6 Suppl):364S-370S. PubMed ID: 14668419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fondaparinux: a new antithrombotic agent.
    Cheng JW
    Clin Ther; 2002 Nov; 24(11):1757-69; discussion 1719. PubMed ID: 12501872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials.
    Davidson BL; Büller HR; Decousus H; Gallus A; Gent M; Piovella F; Prins MH; Raskob GE; Segers AE; Lensing AW;
    J Thromb Haemost; 2007 Jun; 5(6):1191-4. PubMed ID: 17403087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery.
    Turpie AG; Eriksson BI; Lassen MR; Bauer KA
    J South Orthop Assoc; 2002; 11(4):182-8. PubMed ID: 12597061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery.
    Gordois A; Posnett J; Borris L; Bossuyt P; Jönsson B; Levy E; de Pouvourville G
    J Thromb Haemost; 2003 Oct; 1(10):2167-74. PubMed ID: 14521600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heparin pentasaccharide.
    Gallus AS; Coghlan DW
    Curr Opin Hematol; 2002 Sep; 9(5):422-9. PubMed ID: 12172461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery.
    Raskob GE; Hirsh J
    Chest; 2003 Dec; 124(6 Suppl):379S-385S. PubMed ID: 14668421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Setting a standard for venous thromboembolism prophylaxis.
    Turpie AG
    Am J Health Syst Pharm; 2001 Nov; 58 Suppl 2():S18-23. PubMed ID: 11715835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacoeconomics of thrombosis management.
    Hawkins D
    Pharmacotherapy; 2004 Jul; 24(7 Pt 2):95S-99S. PubMed ID: 15317405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prevention and treatment of venous thromboses and thromboembolism: pentasaccharides as novel anticoagulants selectively blocking Xe factor, their position and potential (data of the XIX International Congress on Thromboses and Hemostasis)].
    Averkov OV
    Angiol Sosud Khir; 2004; 10(3):12-23. PubMed ID: 15622389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.
    Eriksson BI; Bauer KA; Lassen MR; Turpie AG;
    N Engl J Med; 2001 Nov; 345(18):1298-304. PubMed ID: 11794148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery.
    Shorr AF; Sarnes MW; Peeples PJ; Stanford RH; Happe LE; Farrelly E
    Am J Health Syst Pharm; 2007 Nov; 64(22):2349-55. PubMed ID: 17989444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux).
    Samama MM; Gerotziafas GT
    Thromb Res; 2003 Jan; 109(1):1-11. PubMed ID: 12679126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty.
    Cafri G; Paxton EW; Chen Y; Cheetham CT; Gould MK; Sluggett J; Bini SA; Khatod M
    J Arthroplasty; 2017 Nov; 32(11):3524-3528.e1. PubMed ID: 28634095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prophylaxis against venous thromboembolism in orthopedic surgery.
    Liu LT; Ma BT
    Chin J Traumatol; 2006 Aug; 9(4):249-56. PubMed ID: 16849000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa.
    Petitou M; Duchaussoy P; Herbert JM; Duc G; El Hajji M; Branellec JF; Donat F; Necciari J; Cariou R; Bouthier J; Garrigou E
    Semin Thromb Hemost; 2002 Aug; 28(4):393-402. PubMed ID: 12244487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fondaparinux sodium.
    Reverter JC
    Drugs Today (Barc); 2002 Mar; 38(3):185-94. PubMed ID: 12532174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
    Huisman MV; Bounameaux H
    Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.